Martin Landray

• A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease.

  Schlackow I. et al, (2017), Heart

• Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.

  Baigent C. et al, (2017), Kidney Int, 92, 297 - 305

• Improving public health by improving clinical trial guidelines and their application.

  Landray MJ. et al, (2017), Eur Heart J, 38, 1632 - 1637

• Biliary Tract and Liver Complications in Polycystic Kidney Disease.

  Judge PK. et al, (2017), J Am Soc Nephrol

• Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.

  Landray MJ. et al, (2017), Am Heart J, 187, 182 - 190

• Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection.

  Reith C. et al, (2017), BMC Nephrol, 18

• Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP).

  Staplin N. et al, (2017), Clin J Am Soc Nephrol, 12, 546 - 552

• Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.

  Herrington W. et al, (2017), Hypertension, 69, 314 - 322

• Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.

  Mafham MM. et al, (2017), Nephrol Dial Transplant

• Feasibility of Obtaining Measures of Lifestyle From a Smartphone App: The MyHeart Counts Cardiovascular Health Study.

  McConnell MV. et al, (2017), JAMA Cardiol, 2, 67 - 76

• Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).

  Staplin N. et al, (2016), Am J Kidney Dis, 68, 371 - 380

• Enhancing clinical evidence by proactively building quality into clinical trials.

  Meeker-O'Connell A. et al, (2016), Clin Trials, 13, 439 - 444

• Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.

  Cholesterol Treatment Trialists' (CTT) Collaboration None. et al, (2016), Lancet Diabetes Endocrinol, 4, 829 - 839

• Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.

  Kent S. et al, (2016), Circ Cardiovasc Qual Outcomes, 9, 348 - 354

• Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).

  Mihaylova B. et al, (2016), Am J Kidney Dis, 67, 576 - 584

• Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology.

  Jackson N. et al, (2016), Eur Heart J, 37, 747 - 754

• Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD.

  Morton RL. et al, (2016), Am J Kidney Dis, 67, 31 - 39

• Cognitive aging and the incidence of cardiovascular events and diabetes: a meta-analysis of the HPS, SEARCH and HPS2-THRIVE studies

  Parish S. et al, (2015), EUROPEAN HEART JOURNAL, 36, 981 - 981

• Neprilysin inhibition in chronic kidney disease.

  Judge P. et al, (2015), Nephrol Dial Transplant, 30, 738 - 743

• IMPACT OF EDUCATIONAL ATTAINMENT ON HEALTH OUTCOMES IN MODERATE-TO-SEVERE CHRONIC KIDNEY DISEASE

  Morton RL. et al, (2015), NEPHROLOGY DIALYSIS TRANSPLANTATION, 30

• What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?

  Kent S. et al, (2015), BMC Nephrol, 16

• UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.

  Sudlow C. et al, (2015), PLoS Med, 12

• Alemtuzumab induction therapy in kidney transplantation - Authors' reply.

  Haynes R. et al, (2015), Lancet, 385

• Use of gel-based separator tubes to stabilise phosphate in mailed blood samples.

  Herrington W. et al, (2015), Clin Chim Acta, 439, 112 - 114

• Evidence for the Prevention and Treatment of Stroke in Dialysis Patients

  Herrington W. et al, (2015), Seminars in Dialysis, 28, 35 - 47

• Evidence for the prevention and treatment of stroke in dialysis patients.

  Herrington W. et al, (2015), Semin Dial, 28, 35 - 47

• Adding niacin plus laropiprant to statins did not reduce vascular events and increased serious adverse events

  Landray MJ. et al, (2014), ANNALS OF INTERNAL MEDICINE, 161, JC8 - JC8

• Niacin for reduction of cardiovascular risk.

  Landray MJ. et al, (2014), N Engl J Med, 371, 1943 - 1944

• Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.

  3C Study Collaborative Group None. et al, (2014), Lancet, 384, 1684 - 1690

• Effects of lowering LDL cholesterol on progression of kidney disease.

  Haynes R. et al, (2014), J Am Soc Nephrol, 25, 1825 - 1833

• Effects of extended-release niacin with laropiprant in high-risk patients.

  HPS2-THRIVE Collaborative Group None. et al, (2014), N Engl J Med, 371, 203 - 212

• Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation

  Haynes R. et al, (2014), TRANSPLANTATION, 98, 155 - 155

• Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).

  Haynes R. et al, (2014), Am J Kidney Dis, 64, 40 - 48

• Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation

  Haynes R. et al, (2014), AMERICAN JOURNAL OF TRANSPLANTATION, 14, 155 - 155

• The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.

  Herrington W. et al, (2014), Clin J Am Soc Nephrol, 9, 914 - 919

• Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)

  Haynes R. et al, (2014), American Journal of Kidney Diseases, 64, 40 - 48

• Randomized clinical trials--removing obstacles.

  Reith C. et al, (2013), N Engl J Med, 369

• Randomized clinical trials--removing unnecessary obstacles.

  Reith C. et al, (2013), N Engl J Med, 369, 1061 - 1065

• Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol.

  Haynes R. et al, (2013), Transplant Res, 2

• HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

  HPS2-THRIVE Collaborative Group None., (2013), Eur Heart J, 34, 1279 - 1291

• [ACEI/ARB use among high risk patients with coronary heart disease in China: a cross-sectional study].

  Liu JM. et al, (2013), Zhonghua Xin Xue Guan Bing Za Zhi, 41, 18 - 22

• Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16, 860 patients.

  Li J. et al, (2012), Chin Med J (Engl), 125, 4361 - 4367

• Clinical Trials: Rethinking How We Ensure Quality

  Landray MJ. et al, (2012), Drug Information Journal, 46, 657 - 660

• The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.

  Cholesterol Treatment Trialists' (CTT) Collaborators None. et al, (2012), Lancet, 380, 581 - 590

• Underuse of statins in patients with atherosclerotic ischemic stroke in China.

  Li X. et al, (2012), Chin Med J (Engl), 125, 1703 - 1707

• Serum free light chains and the risk of ESRD and death in CKD.

  Haynes R. et al, (2011), Clin J Am Soc Nephrol, 6, 2829 - 2837

• Benefits of lowering cholesterol in chronic kidney disease - Authors' reply

  Baigent C. et al, (2011), The Lancet, 378, 1377 - 1378

• The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

  Baigent C. et al, (2011), Lancet, 377, 2181 - 2192

• Survey of treatment of hypertension among patients with ischemic stroke

  Li J. et al, (2011), Chin J Hypert, 19, 246 - 250

• Ezetimibe/simvastatin (vytorin) in heart and renal protection: The SHARP trial

  Alexander W. et al, (2011), P and T, 36

• Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis.

  Mafham M. et al, (2011), PLoS One, 6

• Prediction of ESRD and death among people with CKD: The chronic renal impairment in Birmingham (CRIB) prospective cohort study

  Landray MJ. et al, (2010), American Journal of Kidney Diseases, 56, 1082 - 1094

• Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.

  Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group None. et al, (2010), Lancet, 376, 1658 - 1669

• Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

  Baigent C. et al, (2010), AMERICAN HEART JOURNAL, 160, 785 - U28

• Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.

  Emberson JR. et al, (2010), J Intern Med, 268, 145 - 154

• Low Use of Statins among High-risk Patients in China

  Jiang L. et al, (2010), CIRCULATION, 122, E270 - E270

• Lipids in chronic kidney disease.

  Lewis D. et al, (2010), J Ren Care, 36 Suppl 1, 27 - 33

• Survey of statin usage in 4429 diabetic patients with atherosclerostic cardiovascular disease in China

  Jiang L. et al, (2010), Chin J Cardiovasc Med, 15, 264 - 268

• Cross-sectional study of statin use among high-risk patients with coronary heart disease in China

  Li J. et al, (2010), Chin Circ J, 25, 348 - 351

• A cross-sectional study on the use of statin among patients with atherosclerotic ischemic stroke in China

  Jiang L. et al, (2010), Chin J Epidemiol, 31, 925 - 928

• Dual blockade of the renin-angiotensin system: are two better than one?

  Haynes R. et al, (2009), Nephrol Dial Transplant, 24, 3602 - 3607

• Reassuring results with regard to the effect of donor nephrectomy on cardiovascular outcomes.

  Haynes R. et al, (2009), Nat Clin Pract Nephrol, 5, 126 - 127

• Commentary: Controversies in NICE guidance on chronic kidney disease

  Landray MJ. and Haynes RJ., (2008), BMJ, 337, 815 - 816

• Commentary: Controversies in NICE guidance on chronic kidney disease.

  Landray MJ. and Haynes RJ., (2008), BMJ, 337

• Analyses of cancer data from three ezetimibe trials.

  Peto R. et al, (2008), N Engl J Med, 359, 1357 - 1366

• Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials.

  Baigent C. et al, (2007), Semin Dial, 20, 498 - 503

• Increased MGUS prevelance in chronic kidney disease patients

  Hutchinson CA. et al, (2007), HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 92, 198 - 198

• Chronic kidney disease patients and renal transplant recipients rave an increased incidence of monoclonal gammopathies.

  Hutchison CA. et al, (2007), AMERICAN JOURNAL OF KIDNEY DISEASES, 49, A46 - A46

• Which cardiovascular risk factors matter in chronic kidney disease?

  Baigent C. and Landray M., (2007), Nephrol Dial Transplant, 22, 9 - 11

• Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study.

  Zehnder D. et al, (2007), Nephron Clin Pract, 107, c109 - c116

• Chronic kidney disease patients and renal transplant recipients have a high prevalent rate of MGUS

  Hutchison C. et al, (2007), NEPHROLOGY DIALYSIS TRANSPLANTATION, 22, 256 - 256

• A practical method of measuring glomerular filtration rate by iohexol clearance using dried capillary blood spots.

  Mafham MM. et al, (2007), Nephron Clin Pract, 106, c104 - c112

• The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.

  Landray M. et al, (2006), Am J Kidney Dis, 47, 385 - 395

• Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials

  Clarke R. et al, (2005), AMERICAN JOURNAL OF CLINICAL NUTRITION, 82, 806 - 812

• SERUM LIPIDS DO NOT PREDICT CARDIOVASCULAR OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS

  Landray MJ. et al, (2005), NEPHROLOGY, 10, A152 - A152

• ELEVATED LEVELS OF N-TERMINAL BRAIN NATRIURETIC PEPTIDE AND TROPONIN T CORRELATE WITH KIDNEY FUNCTION AND PREDICT OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS

  Landray MJ. et al, (2005), NEPHROLOGY, 10, A152 - A152

• ELEVATED LEVELS OF ASYMMETRIC DIMETHYLARGININE (ADMA) AND SYMMETRIC DIMETHYLARGININE (SDMA) CORRELATE WITH KIDNEY FUNCTION AND PREDICT OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS

  Landray MJ. et al, (2005), NEPHROLOGY, 10, A152 - A152

• First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.

  Baigent C. et al, (2005), Am J Kidney Dis, 45, 473 - 484

• Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials.

  Baigent C. et al, (2004), Curr Opin Nephrol Hypertens, 13, 601 - 605

• Testing the practical aspects of therapeutics by objective structured clinical examination.

  Langford NJ. et al, (2004), J Clin Pharm Ther, 29, 263 - 266

• Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study.

  Landray MJ. et al, (2004), Am J Kidney Dis, 43, 244 - 253

• Two-year survival among patients with chronic-kidney disease not on dialysis: The chronic renal impairment in Birmingham (CRIB) study.

  Nuttall SL. et al, (2003), JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 14, 197A - 197A

• Biochemical safety and efficacy of co-administration of Ezetimibe and simvastatin among patients with chronic kidney disease: The second UK-Heart and renal protection (UK-HARP-II) study

  Landray MJ. et al, (2003), CIRCULATION, 108, 736 - 736

• Study of Heart and Renal Protection (SHARP).

  Baigent C. and Landry M., (2003), Kidney Int Suppl, S207 - S210

• Homocysteine, renal function, and risk of cardiovascular disease.

  Clarke R. et al, (2003), Kidney Int Suppl, S131 - S133

• Cardiovascular risk factors in predialysis patients: baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study.

  Wheeler DC. et al, (2003), Kidney Int Suppl, S201 - S203

• Evaluating treatment effects reliably.

  Landray MJ. and Whitlock G., (2002), BMJ, 325, 1372 - 1373

• ABC of antithrombotic therapy: An overview of antithrombotic therapy.

  Blann AD. et al, (2002), BMJ, 325, 762 - 765

• Impact of prior myocardial infarction and vascular disease on the risk of subsequent cardiac events among 68 730 patients commencing dialysis.

  Landray MJ. et al, (2002), JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 13, 436A - 436A

• The cardioprotective role of beta-blockers in patients with diabetes mellitus.

  Landray MJ. et al, (2002), J Clin Pharm Ther, 27, 233 - 242

• Oxidative stress in malignant and non-malignant phase hypertension.

  Lip GY. et al, (2002), J Hum Hypertens, 16, 333 - 336

• Abnormal low-density lipoprotein subfraction profile in patients with untreated hypertension.

  Landray MJ. et al, (2002), QJM, 95, 165 - 171

• Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment.

  Landray MJ. et al, (2001), Am J Kidney Dis, 38, 537 - 546

• Renal function: an emerging risk factor for cardiovascular disease?

  Landray MJ. and Baigent C., (2001), Evid Based Cardiovasc Med, 5, 32 - 33

• Predicting left ventricular systolic dysfunction

  Dobbs F. et al, (2000), BMJ, 321

• Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: cross-sectional study.

  Landray MJ. et al, (2000), BMJ, 320, 985 - 986

• Pyrexia, anaemia and acute renal failure secondary to omeprazole.

  Landray MJ. et al, (1998), Postgrad Med J, 74, 416 - 418

Recent Publications

• A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease.

  Schlackow I. et al, (2017), Heart

• Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.

  Baigent C. et al, (2017), Kidney Int, 92, 297 - 305

• Improving public health by improving clinical trial guidelines and their application.

  Landray MJ. et al, (2017), Eur Heart J, 38, 1632 - 1637

• Biliary Tract and Liver Complications in Polycystic Kidney Disease.

  Judge PK. et al, (2017), J Am Soc Nephrol

• Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.

  Landray MJ. et al, (2017), Am Heart J, 187, 182 - 190